Bio-Thera Solutions 過去の業績

過去基準チェック /06

Bio-Thera Solutionsは16.9%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで5.9%毎年増加している。売上は成長しており、年平均34.9%の割合である。

主要情報

16.9%

収益成長率

21.7%

EPS成長率

Biotechs 業界の成長	11.3%
収益成長率	34.9%
株主資本利益率	-44.6%
ネット・マージン	-45.8%
次回の業績アップデート	25 Nov 2024

Recent updates

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Oct 09

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Sep 05

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04

収支内訳

Bio-Thera Solutions の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SHSE:688177 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	825	-378	255	758
30 Jun 24	792	-378	228	751
31 Mar 24	711	-371	211	709
31 Dec 23	705	-395	201	769
30 Sep 23	534	-607	187	804
30 Jun 23	541	-565	189	770
31 Mar 23	536	-513	184	705
31 Dec 22	455	-480	174	616
30 Sep 22	803	-62	191	593
30 Jun 22	737	-90	201	582
31 Mar 22	850	81	210	549
31 Dec 21	837	82	216	543
30 Sep 21	492	-263	221	539
30 Jun 21	463	-267	209	546
31 Mar 21	223	-513	181	594
31 Dec 20	183	-513	164	563
30 Sep 20	106	-501	115	522
30 Jun 20	49	-551	86	529
31 Mar 20	20	-600	71	567
31 Dec 19	1	-1,023	401	637
30 Sep 19	1	-1,075	408	1,053
31 Dec 18	0	-553	26	542
31 Dec 17	2	-236	12	237
31 Dec 16	3	-137	11	132

質の高い収益: 688177は現在利益が出ていません。

利益率の向上: 688177は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 688177は利益を出していないが、過去 5 年間で年間16.9%の割合で損失を削減してきた。

成長の加速: 688177の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 688177は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 0.08% ) と比較することは困難です。

株主資本利益率

高いROE: 688177は現在利益が出ていないため、自己資本利益率 ( -44.57% ) はマイナスです。

Bio-Thera Solutions 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi, bevacizumab), A Biosimilar Referencing Avastin

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, A Proposed Biosimilar of Keytruda (Pembrolizumab)

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, A Proposed Biosimilar to Stelara in the US and EU

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin

Price target decreased by 22% to CN¥42.10

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Full year 2023 earnings released: CN¥0.97 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026

FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara

Third quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.21 loss in 3Q 2022)

Chugai Pharmaceutical Co., Ltd., Roche, Genentech, Biogen MA Inc. and Bio-Thera Solutions, Ltd. Withdraw Lawsuit

FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration

Second quarter 2023 earnings released: CN¥0.27 loss per share (vs CN¥0.14 loss in 2Q 2022)

Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum

Chugai Files Patent Infringement Lawsuit Against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S

First quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.27 loss in 1Q 2022)

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306

Third quarter 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.28 loss in 3Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala (mepolizumab)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 profit in 2Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for Bat8009, an Antibody Drug Conjugate Targeting B7-H3 (Cd276) for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, Ltd Announces First Patient Dosed in Phase 1 Study for Bat8006, an Antibody Drug Conjugate Targeting Folate Receptor A for the Treatment of Advanced Solid Tumors

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

First quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.26 loss in 1Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study in Australia Evaluating BAT6026, Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, Anti-PD-1 Antibody

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Australia for BAT6021, ADCC-Enhanced Monoclonal Antibody Targeting TIGIT for Treatment of Solid Tumors

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥1.08 (vs CN¥0.34 loss in 2Q 2020)

Bio-Thera Solutions Announces First Patient Dosed in Phase III Clinical Trial for BAT2206

Bio-Thera Solutions Initiates Phase Iii Clinical Trial for Bat2506, A Proposed Biosimilar of Simponi® (Golimumab)

Biogen and Bio-Thera Announces Positive Results From Phase 3 Study of BAT1806

First quarter 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.28 loss in 1Q 2020)

New 90-day low: CN¥25.00

Full year 2020 earnings released: CN¥1.27 loss per share (vs CN¥2.96 loss in FY 2019)

New 90-day low: CN¥25.03

Bio-Thera Solutions,Ltd. Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®

Bio-Thera Solutions, Ltd. Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Bio-Thera Solutions,Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥29.33

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day low: CN¥34.21

Bio-Thera Solutions,Ltd. Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

New 90-day low: CN¥38.59

Bio-Thera Solutions,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥43.33

New 90-day low: CN¥43.73

New 90-day low - CN¥47.10

New 90-day low - CN¥47.90

Bio-Thera Solutions, Ltd. to Report First Half, 2020 Results on Aug 28, 2020

収支内訳

収益と収入の歴史

過去基準チェック /06